5d3d | pdb_00005d3d
Crystal structure of Staphylococcal Superantigen-Like protein 3
Structural highlights
FunctionSSL3_STAA8 Secreted protein that plays an essential role in immune innate response inhibition by interacting with and inhibiting host TLR2. In turn, bacteria recognition by immune cells is impaired and cytokine production is inhibited (PubMed:22665377, PubMed:22714643). Mechanistically, by interacting with TLR2, blocks ligand binding and thus inhibits activation (PubMed:26283364). Second, by interacting with an already formed TLR2-lipopeptide complex, prevents TLR heterodimerization and downstream signaling. The interaction with host TLR2 does not involve sialyl Lewis X interactions (PubMed:26283364).[1] [2] [3] Publication Abstract from PubMedToll-like receptors (TLRs) are crucial in innate recognition of invading micro-organisms and their subsequent clearance. Bacteria are not passive bystanders and have evolved complex evasion mechanisms. Staphylococcus aureus secretes a potent TLR2 antagonist, staphylococcal superantigen-like protein 3 (SSL3), which prevents receptor stimulation by pathogen-associated lipopeptides. Here, we present crystal structures of SSL3 and its complex with TLR2. The structure reveals that formation of the specific inhibitory complex is predominantly mediated by hydrophobic contacts between SSL3 and TLR2 and does not involve interaction of TLR2-glycans with the conserved LewisX binding site of SSL3. In the complex, SSL3 partially covers the entrance to the lipopeptide binding pocket in TLR2, reducing its size by approximately 50%. We show that this is sufficient to inhibit binding of agonist Pam2CSK4 effectively, yet allows SSL3 to bind to an already formed TLR2-Pam2CSK4 complex. The binding site of SSL3 overlaps those of TLR2 dimerization partners TLR1 and TLR6 extensively. Combined, our data reveal a robust dual mechanism in which SSL3 interferes with TLR2 activation at two stages: by binding to TLR2, it blocks ligand binding and thus inhibits activation. Second, by interacting with an already formed TLR2-lipopeptide complex, it prevents TLR heterodimerization and downstream signaling. Structural basis for inhibition of TLR2 by staphylococcal superantigen-like protein 3 (SSL3).,Koymans KJ, Feitsma LJ, Brondijk TH, Aerts PC, Lukkien E, Lossl P, van Kessel KP, de Haas CJ, van Strijp JA, Huizinga EG Proc Natl Acad Sci U S A. 2015 Aug 17. pii: 201502026. PMID:26283364[4] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
| ||||||||||||||||||
